ExodusPoint Capital Management’s Intercept Pharmaceuticals, Inc. ICPT Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Change in Stake | Trade Value | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2023
Q4 | – | Sell |
-35,087
| Closed | -$651K | – | 2180 |
|
|
2023
Q3 | $651K | Sell |
35,087
-106,132
| -75% | -$1.2M | 0.01% | 1144 |
|
|
2023
Q2 | $1.56M | Buy |
141,219
+63,661
| +82% | +$887K | 0.01% | 912 |
|
|
2023
Q1 | $1.04M | Sell |
77,558
-453,009
| -85% | -$7.84M | 0.01% | 1129 |
|
|
2022
Q4 | $6.56M | Buy |
530,567
+446,628
| +532% | +$6.32M | 0.1% | 278 |
|
|
2022
Q3 | $1.17M | Buy |
+83,939
| New | +$1.35M | 0.02% | 1047 |
|
|
2022
Q2 | – | Sell |
-34,745
| Closed | -$565K | – | 2613 |
|
|
2022
Q1 | $565K | Sell |
34,745
-122,918
| -78% | -$1.93M | 0.01% | 1456 |
|
|
2021
Q4 | $2.57M | Buy |
157,663
+129,030
| +451% | +$2.18M | 0.03% | 662 |
|
|
2021
Q3 | $425K | Buy |
28,633
+17,998
| +169% | +$288K | 0.01% | 1481 |
|
|
2021
Q2 | $212K | Sell |
10,635
-7,420
| -41% | -$147K | ﹤0.01% | 1954 |
|
|
2021
Q1 | $417K | Sell |
18,055
-874
| -5% | -$24.4K | 0.01% | 1480 |
|
|
2020
Q4 | $468K | Buy |
+18,929
| New | +$627K | ﹤0.01% | 1293 |
|
|
2020
Q3 | – | Sell |
-40,941
| Closed | -$1.96M | – | 2344 |
|
|
2020
Q2 | $1.96M | Buy |
+40,941
| New | +$3.16M | 0.05% | 432 |
|
|
2019
Q3 | – | Sell |
-3,400
| Closed | -$271K | – | 1718 |
|
|
2019
Q2 | $271K | Buy |
3,400
+1,604
| +89% | +$144K | 0.01% | 751 |
|
|
2019
Q1 | $201K | Buy |
+1,796
| New | +$196K | 0.02% | 565 |
|
ExodusPoint Capital Management's ICPT Position: Q4 2023 in Review
ExodusPoint Capital Management sold out of Intercept Pharmaceuticals, Inc. (ICPT) in Q4 2023, closing a stake of 35,087 shares — an estimated $651K sold.
ExodusPoint Capital Management first reported a position in ICPT in Q1 2019 and held it in 14 quarters. The position peaked at $6.56M in Q4 2022. 0 funds tracked by Wall St. Rank hold ICPT as of Q4 2023.
- ExodusPoint Capital Management reported no remaining Intercept Pharmaceuticals, Inc. position as of Q4 2023 after selling out during the quarter.
- ExodusPoint Capital Management sold 35,087 Intercept Pharmaceuticals, Inc. shares in Q4 2023, an estimated $651K.
- ExodusPoint Capital Management first reported a position in Intercept Pharmaceuticals, Inc. in Q1 2019 and held it in 14 quarters.
- ExodusPoint Capital Management's Intercept Pharmaceuticals, Inc. position peaked at $6.56M in Q4 2022.
- 0 funds tracked by Wall St. Rank held Intercept Pharmaceuticals, Inc. as of Q4 2023.
Based on ExodusPoint Capital Management's 13F filing for Q4 2023, filed 14 Feb 2024.